Streamlining Biotherapy QC: Practical Solutions for Protein Analytics & Residual DNA Testing

Biologic therapies are transforming healthcare, but their complexity brings unique challenges for downstream quality control (QC). Ensuring product purity, safety, and consistency requires precise and reliable analytical methods, especially in the face of regulatory scrutiny. Two critical areas of focus are HPLC protein analytics and residual DNA testing, both of which present technical hurdles that can delay production timelines if not addressed effectively.

This webinar will explore the most common QC bottlenecks encountered during downstream biotherapy manufacturing, with a practical lens on HPLC protein analytics and residual DNA testing. We’ll highlight common pitfalls, debunk myths, and offer strategies to improve robustness and reproducibility.

Participants will gain insight into how proactive QC planning—rather than reactive troubleshooting—can help streamline biotherapeutic development, reduce compliance risks, and ultimately accelerate the path to market.